Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × Lenalidomide × Clear all

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-03-03

EPCORE DLBCL-3

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT04978584 2025-10-27

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04460248 2025-05-02

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05335018 2024-12-16

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06669143 2024-11-01

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06503263 2024-09-19

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT00799513 2024-04-10

RV-NHL-PI351

Phase 2 Completed

48 enrolled 17 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06176729 2023-12-20

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05290090 2023-10-17

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT03019640 2023-02-16

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2 Completed

22 enrolled 8 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04113226 2023-02-08

Relyage

Phase 2 Unknown

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05575973 2022-10-12

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT05200312 2022-03-11

ZR2-CHOP

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT03837873 2022-01-26

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04544059 2020-09-10

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT02060656 2019-09-19

LEGEND

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01419795 2017-07-27

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Phase 2 Terminated

3 enrolled 10 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT00765245 2016-04-11

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

44 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00474188 2009-09-02

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Terminated

26 enrolled 5 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse